trending Market Intelligence /marketintelligence/en/news-insights/trending/dnlydwhigkab3nwg5jisug2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

NovaBay Pharmaceuticals director resigns; replacement named

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


NovaBay Pharmaceuticals director resigns; replacement named

NovaBay Pharmaceuticals Inc. appointed Yanbin Liu as a director after the resignation of Xiaoyan Liu, effective March 21.

Xiaoyan Liu did not resign due to any disagreements on any matter relating to the company's operations, policies or practices, according to NovaBay.

Yanbin Liu, a non-independent board member, will takeover Xiaoyan Liu's place as a class III director to serve until the annual stockholders' meeting in 2019. He has served as the joint COO and head of direct investment of OP Financial Investments Ltd. in Hong Kong since February 2015.

OP Financial has a significant investment in NovaBay and Yanbin Liu was appointed as a representative of OP Financial.

Emeryville, Calif.-based NovaBay Pharmaceuticals is a pharmaceutical company that develops, manufactures and markets anti-infective products for the eye care market in the U.S.